1. Home
  2. CANF vs SSKN Comparison

CANF vs SSKN Comparison

Compare CANF & SSKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CANF
  • SSKN
  • Stock Information
  • Founded
  • CANF 1994
  • SSKN 1989
  • Country
  • CANF Israel
  • SSKN United States
  • Employees
  • CANF N/A
  • SSKN N/A
  • Industry
  • CANF Biotechnology: Pharmaceutical Preparations
  • SSKN Medical/Dental Instruments
  • Sector
  • CANF Health Care
  • SSKN Health Care
  • Exchange
  • CANF Nasdaq
  • SSKN Nasdaq
  • Market Cap
  • CANF 9.6M
  • SSKN 8.9M
  • IPO Year
  • CANF N/A
  • SSKN 2005
  • Fundamental
  • Price
  • CANF $0.63
  • SSKN $2.38
  • Analyst Decision
  • CANF Strong Buy
  • SSKN Strong Buy
  • Analyst Count
  • CANF 2
  • SSKN 1
  • Target Price
  • CANF $14.00
  • SSKN $6.00
  • AVG Volume (30 Days)
  • CANF 140.0K
  • SSKN 372.2K
  • Earning Date
  • CANF 08-26-2025
  • SSKN 08-13-2025
  • Dividend Yield
  • CANF N/A
  • SSKN N/A
  • EPS Growth
  • CANF N/A
  • SSKN N/A
  • EPS
  • CANF N/A
  • SSKN N/A
  • Revenue
  • CANF $560,000.00
  • SSKN $32,848,000.00
  • Revenue This Year
  • CANF $461.72
  • SSKN N/A
  • Revenue Next Year
  • CANF N/A
  • SSKN $9.70
  • P/E Ratio
  • CANF N/A
  • SSKN N/A
  • Revenue Growth
  • CANF N/A
  • SSKN 0.36
  • 52 Week Low
  • CANF $0.63
  • SSKN $1.61
  • 52 Week High
  • CANF $3.12
  • SSKN $3.79
  • Technical
  • Relative Strength Index (RSI)
  • CANF 29.23
  • SSKN 67.32
  • Support Level
  • CANF $0.64
  • SSKN $1.61
  • Resistance Level
  • CANF $0.68
  • SSKN $2.43
  • Average True Range (ATR)
  • CANF 0.03
  • SSKN 0.22
  • MACD
  • CANF 0.01
  • SSKN 0.07
  • Stochastic Oscillator
  • CANF 2.00
  • SSKN 78.57

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

About SSKN Strata Skin Sciences Inc.

Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.

Share on Social Networks: